Megan Devine is a Respiratory physician affiliated with The University of Texas at Tyler. OpenAlex indexes 31 publications with 1,705 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11937 Us Highway 271
Tyler, TX 757083154
Telephone
903-877-7916Registry record last updated 19 Sept 2016.
Industry payments
41 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year202527 payments
- Boston Scientific CorporationProgram year20258 payments
- GENZYME CORPORATIONProgram year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
57%Corticosteroid21.5%Trelegy Ellipta31%Breo Ellipta20%Symbicort17%Arnuity Ellipta13%Fluticasone Propionate9%Breztri Aerosphere6%Qvar Redihaler5%Part D<11 patientsbeta2-Adrenergic Agonist18.9%Albuterol Sulfate Hfa92%Ventolin Hfa8%Part D≥56 patients+ 6 more classes in this area
Cardiovascular
13.1%Endothelin Receptor Antagonist6.5%Opsumit73%Ambrisentan28%Part D<11 patientsAldosterone antagonist (MRA)2.9%Spironolactone100%Part D<11 patients+ 2 more classes in this area
Anti-infectives
11.2%Macrolide Antimicrobial7.2%Azithromycin100%Part D≥20 patientsShort-acting sulfonamides3%Sulfamethoxazole-Trimethoprim100%Part D≥15 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Rifamycin-, macrolide-, and ethambutol-free combinations to treat <i>Mycobacterium avium</i> complex lung disease
The International Journal of Tuberculosis and Lung Disease
2026 - Two randomised controlled phase 2 studies of the oral neutrophil elastase inhibitor alvelestat in alpha-1 antitrypsin deficiency
European Respiratory Journal
2025 - Mycobacteria susceptibility to epetraborole: how far can it go?
The International Journal of Tuberculosis and Lung Disease
2025 - Granulomas or Not? A Diagnostic Dilemma in Pulmonary Pathology
American Journal of Respiratory and Critical Care Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Jarett Berry, MD
The University of Texas at Tyler
Habte Yimer, MD
The University of Texas at Tyler
Paul Detwiler, MD
The University of Texas at Tyler
Jose Serpa-Alvarez, MD
The University of Texas at Tyler
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Marshall University
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”